THE 5-SECOND TRICK FOR AZELAPRAG CLINICAL TRIALS

The decision follows observations of liver transaminitis with no clinically sizeable indications, and with out very clear dose dependence, in a few clients during the azelaprag arms with the STRIDES Period 2 clinical trial for obesity (hyperlink).To complicate this even more, tirzepatide alone might have synergized improperly with Azelaprag to caus